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Background: Epidemiologic and clinical data have suggested the existence of a biologic 
linkage between the bone system and the vascular system. Bisphosphonates (BPs) are effective 
inhibitors of bone resorption and are currently considered the drugs of choice for the preven-
tion and treatment of osteoporosis and related fractures. Data from several publications have 
suggested that BPs may also be effective in reducing the atherosclerotic process and vascular 
calcification, but the results of these studies are contrasting. This review aimed to allow a better 
understanding of the relationships between BPs and atherosclerosis in humans.
Materials and methods: Electronic databases of Pubmed-Medline, Cochrane Library and 
SCOPUS from inception to June 30, 2016 were searched. The full texts of the articles potentially 
eligible were carefully assessed and reviewed. Finally, 20 studies were found to be eligible and 
were included in the systematic review. All included studies were published between 2000 
and 2014.
Results: In several studies, etidronate limited the progression of aortic and coronary calcification 
in hemodialysis patients, whereas the nitrogen-containing-BPs given orally did not significantly 
reduce vascular calcifications in patients with chronic kidney disease, kidney trasplant or in 
those with osteoporosis. Nitrogen-containing-BPs present favorable effects both on vessel wall 
thickness and on arterial elasticity due to both a reduction in serum lipids and the interaction of 
BPs with the bone tissue, with the consequent release of bone turnover markers and cytokines 
into the bloodstream.
Conclusion: To sum up, the BPs seem to have the potential of influencing atherosclerosis and 
calcium homeostasis at the level of vascular walls with several possible mechanisms which 
may differ according to the type, potency, dosage and administration route of BPs. Additional 
studies are needed to specifically address the mechanism by which BP use could influence 
cardiovascular morbidity and mortality.
Keywords: bisphosphonates, atherosclerosis, vascular calcification, human studies
Introduction
In the past, osteoporosis and atherosclerosis were considered as separate entities 
with a similar increasing prevalence with aging. Recently, both epidemiologic and 
clinical studies have outlined that patients with low bone mineral density (BMD) are 
at significantly greater risk of developing cardiovascular disease (CVD) as well as 
unexpected cardiovascular events, more severe coronary atherosclerosis and vascular 
calcification.1–6 In addition, it is known that postmenopausal women with osteoporosis 
have an increased risk of developing cardiovascular events and that the increased 
risk is proportional to the severity of osteoporosis.7 These data have also suggested 
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a possible influence of drugs affecting bone metabolism 
on lipid and atherosclerosis mechanisms, or that drugs 
effective on the atherosclerosis process could also be effica-
cious in fracture prevention.3,4 Moreover, there is growing 
evidence that osteoporosis and atherosclerosis share not 
only common risk markers such as aging, smoking, reduced 
physical activity and menopause in women, but also some 
pathophysiologic mechanisms and some genetic causes. For 
example, mutations with loss of function of LRP6 in humans 
lead to increased plasma low-density lipoprotein-cholesterol 
(LDL-C), hypertension and osteoporosis.8
An initial interesting theory was that CVD and osteopo-
rosis were linked by a common denominator, such as serum 
lipid profile, which could act in parallel on both vascular and 
bone cells.9 Some experimental data seemed to reinforce 
this concept showing an influence of lipids on osteoblasts 
and osteoclasts.10–12 However, an interesting observational 
study showed that in a multiple regression analysis, lipid 
profile did not predict osteoporosis or fracture risk, whereas 
aortic calcification severity significantly explained BMD 
at the hip.13 On the other hand, low BMD at the distal 
radius was found to be associated with increased risk of 
stroke and CVD mortality.6 Several studies have reported 
that the progression of arterial calcification is linked with 
concurrent bone loss and vertebral fractures, further sup-
porting a relationship between osteoporosis and CVD.14,15 
The common finding of simultaneous vascular calcification 
and osteoporosis in individual patients suggests that local 
tissue factors could have a crucial role in the regulation of 
mineralization and cell differentiation.16 Cardiovascular 
calcification was conventionally viewed as an inevitable 
consequence of aging, but some landmark studies have 
demonstrated that it is a highly regulated process of min-
eralization which involves cellular and molecular signaling 
processes similar to those found in normal osteogenesis.17–20 
The similarity of the molecular mechanisms in osteogen-
esis and vascular calcification has led to the knowledge 
that atherosclerotic calcification is an actively regulated 
process, not a passive mineralization.21 In fact, the mineral 
matrix of the plaque (hydroxyapatite) is identical to that 
found in bone and the process of vascular calcification, 
similar to bone remodeling, is a regulated process which 
includes both inductive and inhibitory mechanisms.22,23 
Moreover, mineral deposits in atherosclerotic plaque 
result from several different pathways involving meta-
bolic and/or inflammatory processes.24 The major factors 
influencing vascular atherosclerotic calcifications are listed 
in Table 1.
The effects of bisphosphonates on 
atherosclerotic plaque and vascular 
calcifications: experimental studies
The growing evidence that atherosclerosis and osteoporosis 
share several pathophysiologic mechanisms reinforces 
the interest in pharmacologic agents which could inhibit 
bone loss and also provide benefits in terms of slowing the 
progression of atherosclerosis. At present, only bisphospho-
nates (BPs), currently considered the drug of choice for the 
prevention and treatment of osteoporosis, could have this 
potential.50–52 In a mouse model of glucocorticoid-induced 
osteoporosis, denosumab, a human monoclonal antibody tar-
geting RANKL, reduced the progression of atherosclerosis.41 
Moreover, a more recent study reported that denosumab 
reduced spontaneous and induced calcification in an in vitro 
porcine valvular interstitial cell model.53 However, the 
analysis of 2,363 postmenopausal women with osteoporosis 
selected from the participants in the FREEDOM study 
and at high risk of cardiovascular events showed a 3-year 
denosumab treatment had no effect on the progression of 
aortic calcifications or on the incidence of cardiovascular 
Table 1 Factors influencing vascular atherosclerotic calcification
Factor References Action
BPM-2 and 
BPM-4
25, 26 Stimulates osteogenic differentiation by 
acting on Wnt pathway
MGP 27, 28 Antagonizes BMP-2 and prevents 
vascular calcification
Fetuin-A 29, 30 Fetuin-A accumulates at sites of vascular 
calcification and inhibits hydroxyapatite 
formation and vascular calcifications
OPG 31–38 OPG prevents RANKL from binding 
to its receptor
OPG inhibits vascular calcification in 
animals; in humans, there is a positive 
association between OPG and Cv diseases
RANKL 16, 38–41 RANKL stimulates vascular calcification
OPN 27, 42, 43 enhancer of atherosclerosis in animals
In humans, may attenuate vascular 
calcification
FGF23 44, 45 Reduces serum phosphate levels
Biomarker of vascular calcification in 
CKD patients
vitamin D 46–48 Regulates the response to inflammatory 
cytokines
No evidence of any effects on vascular 
calcification
Ox-LDL 49 Induces osteogenic and apoptosis-
mediated calcification of vascular cells
Abbreviations: BPM-2, bone morphogenetic protein-2; BPM-4, bone morpho-
genetic protein-4; CKD, chronic kidney disease; CV, cardiovascular; FGF23, 
fibroblast growth factor 23; MGP, matrix Gla-protein; OPG, osteoprotegerin; OPN, 
osteopontin; Ox-LDL, oxidized low-density lipoprotein; RANKL, receptor activator 
of nuclear factor kappa-B ligand.
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adverse events, compared to placebo.54 Also, odanacatib, a 
cathepsin K inhibitor, may have an anti-atherosclerotic effect; 
but in 2016, the development of odanacatib was discontinued 
after analysis discovered an increased risk of cardiovascular 
events.55 BPs are grouped into two classes according to their 
chemical structure and the molecular mechanism by which 
they inhibit osteoclast activity (Table 2). Members of the first 
generation of BPs are called simple BPs (S-BPs; clodronate 
and etidronate), while those of the second or newer genera-
tion are called nitrogen-containing BPs (N-BPs). The latter 
have a high affinity for the bone tissue where they bind to and 
inhibit the activity of farnesyl pyrophosphate synthase, a key 
regulatory enzyme in the mevalonic acid pathway, leading to 
osteoclast apoptosis.56 The first report of the effects of BPs 
on vascular calcification was published in the 1970s, with 
experiments showing inhibition of soft tissue calcification.57 
The accumulation of BPs in atherosclerotic arteries may be 
due to either their binding to calcified atheromatous lesions 
or their internalization into phagocytosing cells (namely, the 
macrophages).52 Etidronate was the first BP to demonstrate 
the suppression of atherosclerotic lesion formation in the 
arteries of both rats and pigs, although there was no reduction 
in serum calcium and cholesterol.58,59 Lomashvili et al50 found 
that etidronate significantly reduced the calcium content 
in rat aortae cultured in a medium containing warfarin to 
induce calcification, and suggested that S-BPs may prevent 
calcifications by blocking the apatite crystalsformation in the 
vessels as they do in the bone.50 Clodronate at high dosages, 
when administered to rabbits, also significantly reduced the 
area of atherosclerotic lesions in the aorta, total cholesterol 
and total calcium concentration in the aorta.52 S-BPs may 
directly inhibit metalloproteinases60 and the expression of 
tumor necrosis factor-α, a cytokine that promotes osteoblastic 
differentiation of vascular cells and also inhibits calcium 
deposition in the atherosclerotic lesions.61 Moreover, S-BPs 
can be metabolized by the phagocytes into non-hydrolyzable 
adenine-containing analogs of adenosine triphosphate,62 
which inhibit adenine nucleotide translocase, thus promoting 
the activation of caspase-3 and thereby leading to apoptosis 
of macrophages and osteoclasts.63 Several animal studies sug-
gest that N-BPs also may have an inhibitory effect on vascular 
calcification and atherosclerosis process. Alendronate and 
ibandronate are reported to inhibit calcification of arteries and 
cardiac valves in rat models of warfarin-related calcification 
at doses comparable to those that inhibit bone resorption, 
without affecting serum calcium and phosphate levels.64 
Moreover, in uremic rats fed with a low-protein diet, artery 
calcifications were prevented by treatment with ibandronate.65 
Another study reported that high doses of vitamin D were 
lethal to rats and caused excessive calcification of arteries, 
lungs, kidneys and cartilage; however, when subjects were 
given vitamin D plus ibandronate, soft tissue calcification was 
inhibited in all organs and death was prevented.66 Moreover, 
in monkeys, a 2-year treatment with pamidronate inhibited 
the development of diet-induced atherosclerosis without 
significant changes in serum cholesterol and calcium.67 The 
exact mechanism by which N-BPs inhibit vascular calcifi-
cation is not fully clear. It may be by the inhibition of bone 
resorption, with reduced efflux of calcium and phosphate, 
thus limiting their availability for deposition in the vessels or 
their ability to influence the activity of the vascular smooth 
muscle cells NaPi cotransporter.68 Alternatively, N-BPs may 
have direct effects on the vessel wall and/or crystal forma-
tion. Another possible mechanism of action of N-BPs may 
be a reduction in serum cholesterol levels. To sum up, the 
experimental studies have confirmed the ability of BPs to 
reduce the formation of atherosclerotic plaques and to inhibit 
vascular calcifications. In animal studies, etidronate was the 
more potent inhibitor of vascular calcifications.
The effects of BPs on atherosclerotic 
plaque and vascular calcifications: a 
systematic review of clinical studies
This review aimed to collect and synthesize the available 
data, in order to allow a better understanding of the relation-
ships between BPs and atherosclerosis/vascular calcifications 
in humans.
Materials and methods
A literature review was conducted from inception to June 30, 
2016. Pubmed-Medline, Cochrane Library and SCOPUS 
databases were searched using the following search terms 
Table 2 Different potential effects of simple bisphosphonates 
and nitrogen-containing bisphosphonates on vascular calcification
Simple bisphosphonates Nitrogen-containing bisphosphonates
Inhibit metalloproteinases Reduce efflux of calcium and phosphate
Inhibit TNF-α Influence the activity of the vascular 
smooth muscle cell NaPi cotransporter
Promote osteoblastic 
differentiation of vascular 
cells
Direct effects on the vessel wall
Inhibit calcium deposition 
in the atheromatous lesions
Direct effects on formation of crystals on 
the vessel wall, such as pyrophosphate
Promote the activation 
of caspase-3 and induce 
apoptosis of osteoclasts
Induce osteoclast apoptosis by inhibiting 
the farnesyl pyrophosphate synthase
Abbreviation: TNF-α, tumor necrosis factor alpha.
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(“bisphosphonates” or “etidronate” or “alendronate” or 
“risedronate” and so on) AND (“atherosclerosis” or “atheroscle-
rotic plaque” or “cholesterol” or “vascular calcification”).
Study selection
Studies were excluded if they were not available; they were 
on children, animals, in vitro or experimental studies, case 
reports, case series, letters to editor, comments, review 
articles; they were published in languages other than English; 
and they did not fulfill the objective of this review. Original 
studies were included if they met the following inclusion 
criteria: 1) being a clinical study; 2) investigating the impact 
of BPs on atherosclerosis, vascular calcification or serum 
cholesterol and 3) presentation of sufficient information on 
the study parameters at baseline and at the end of follow-up. 
Exclusion criteria were: 1) non-interventional studies; 
2) observational and cross-sectional studies and 3) study 
duration of ,6 months.
Eligible studies were reviewed and the following data 
were extracted: 1) first author’s name; 2) year of publication; 
3) study design; 4) study duration; 5) number of subjects in 
BP and control groups; 6) intervention assigned to the control 
group (placebo, non-active treatment or active treatment); 7) 
outcome measurements evaluated and 8) baseline and end-
study values for the study parameters.
Characteristics of included studies
After the multiple database search, 297 published studies 
were identified and the abstracts reviewed. The study 
selection process is shown in Figure 1. The full text of the 
32 articles potentially eligible were carefully assessed and 
reviewed. Finally, 20 studies were found to be eligible and 
were included in the systematic review.
Results
The characteristics of the 20 studies included in the system-
atic review are presented in Table 3. The included studies 
were published between 2000 and 2014. Similar to animal 
experiments, which reported conflicting results for BP treat-
ment of atherosclerosis and related vascular calcification, 
there have been varying responses in clinical studies.
effects of BPs an intima–media thickening 
and serum cholesterol
More than a decade ago, Adami et al firstly reported a 
significant reduction in LDL-C and an increase in high-
density lipoprotein-cholesterol (HDL-C) in postmenopausal 
women treated with intravenous (i.v.) neridronate, whereas 
no significant changes were observed in total cholesterol.69 
Significant reductions in LDL-C were also reported by other 
two clinical studies carried out, respectively, in patients 
treated with i.v. pamidronate for Paget’s bone disease and 
in patients with smouldering multiple myeloma treated with 
zoledronic acid.70,71 More recently, Gonnelli et al reported 
that in postmenopausal osteoporotic women, a 1-year treat-
ment with both zoledronate (a single yearly injection) and 
ibandronate (a 3-monthly injection) induced similar changes 
in lipid profile by increasing HDL-C and reducing LDL-C and 
resulted in a reduction of intima–media thickness (IMT) at 
the carotid artery; however, in the latter study, no significant 
changes in total cholesterol were observed.72 These positive 
effects of i.v. N-BPs on lipids have not yet been confirmed 
by the majority of studies carried out with N-BPs or S-BPs 
given orally. In particular, a study by Luckish et al carried out 
on osteoporotic women with at least one cardiovascular risk 
factor treated with risedronate 35 mg weekly for 6 months 
reported a significant improvement in artery elasticity, but 
???????????????????????
????????????????????????????
???????????????????????????????
??????????????????????????????????????????????????
?????????????????????????????????????????????????
???????????????????????????????????????????????
??????????????????????????????????????????????????????????????????????????????????????????????????????????????????????
????????????????????????????????????????
??????????????????????????????????????????????????????????
Figure 1 Flow chart of the studies identified and included in the review.
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BPs, atherosclerosis and vascular calcification
no change in HDL-C and LDL-C levels.73 Koshiyama et al74 
investigated the effect of etidronate on carotid IMT in 
patients with type 2 diabetes and reported that at the end of 
a 12-month treatment, IMT was significantly reduced in the 
etidronate group with respect to control participants. Also, 
the study by Celiloglu et al reported that in postmenopausal 
osteoporotic women, a 1-year treatment with alendronate 
significantly reduced carotid IMT with respect to controls.75 
Moreover, in a study carried out on Japanese women with 
diabetes and postmenopausal osteoporosis, a 1-year therapy 
with risedronate (2.5 mg/day) along with alfacalcidiol 
(1 mg/day) significantly reduced the progression of athero-
sclerotic plaques at the carotid arteries and abdominal aorta.76 
On the contrary, the study by Delibasi et al reported that in 
postmenopausal osteoporotic women, a 13-month treatment 
with alendronate did not evidence any changes in carotid 
IMT or serum levels of lipids.77 Also, the study by Igase et al 
reported that in a Japanese population, a 1-year treatment 
with alendronate (35 mg/week) did not improve arterial stiff-
ness.78 Some studies reported that a 12-month treatment with 
etidronate74,79 or alendronate75 induced a nonsignificant 
reduction in total and LDL-C, along with a nonsignificant 
increase in HDL-C. Moreover, Kawahara et al, in a prospec-
tive randomized study carried out in hypercholesterolemic 
patients, reported that atorvastatin plus etidronate combina-
tion therapy was significantly more effective (P,0.001) in 
reducing atherosclerotic plaques in the abdominal aorta than 
both atorvastatin and etidronate monotherapy.79 In the same 
study, the atorvastatin plus etidronate combination therapy 
showed a reduction of the atherosclerotic plaques in thoracic 
aorta similar to that of atorvastatin monotherapy.79 On the 
contrary, a Japanese study carried out on osteoporotic women 
treated with a reduced dose of alendronate (5 mg/day) did 
not find any changes in cholesterol levels.80 To sum up, the 
majority of human studies have reported a reduction of IMT 
at the carotid artery, whereas data on arterial stiffness and the 
atherosclerotic plaques are inconclusive. Moreover, N-BPs 
seem to improve the lipid profile only when given i.v.
Effects of BPs on vascular calcification
Nitta et al reported that in hemodialysis patients, etidronate at 
a dose of 200 mg/day for 2 weeks every 90 days significantly 
reduced coronary artery calcifications, assessed by spiral 
computed tomography, and serum levels of osteoprotegerin.81 
In another study carried out on hemodialysis patients, 
etidronate (400 mg/day for 6 months) decreased aortic cal-
cifications by 65%, whereas aortic calcifications markedly 
increased in controls.82 Another Japanese study carried out 
on hemodialysis patients reported that etidronate (200 mg on 
days of dialysis for 23 months) protected against progression 
of aortic calcifications, whereas these significantly increased 
in the control group.83 A 2-year weekly treatment with 
alendronate in kidney transplant recipients was effective 
in preventing the progression of aortic calcifications with 
respect to control patients (1.4% vs 5%, P=ns).84 Moreover, 
in a study carried out in end-stage chronic kidney disease 
(CKD) patients, an 18-month treatment with alendronate 
significantly decreased the progression of aortic calcification 
with respect to placebo.85 Similarly, Torregrosa et al reported 
that 1-year treatment with residronate (35 mg/week) did not 
significantly influence the progression of vascular calcifica-
tions in kidney transplant patients.86 Another clinical study 
involved osteoporotic women receiving oral or i.v. iban-
dronate for 3 years; at the end of the study period, the effect 
on BMD was positive, whereas no difference was detected 
in the rate of aortic calcification change.87 Moreover, the 
study by Hill et al assessing coronary artery calcification, 
measured by spiral computed tomography scans, in patients 
treated with alendronate 10 mg daily for 2 years matched 
to a cohort of reference subjects did not find any significant 
differences between the two groups.88 To sum up, etidronate 
markedly reduced progression of vascular calcifications, but 
most of these studies were carried out in patients with CKD 
or in hemodialysis. The effects of N-BPs given orally on the 
vascular calcifications were modest and inconclusive.
Discussion
The interest in the relationships between BPs and atheroscle-
rosis has recently shown a further increase after the publica-
tion of the results of the HORIZON study which reported a 
28% reduction in mortality in hip fracture patients treated 
with an annual i.v. dose of zoledronic acid.89 In another study, 
Kang et al revealed that patients who received BP therapy 
for osteoporotic fracture had a lower hazard of myocardial 
infarction during the 2-year follow-up period with respect 
to controls.90 Moreover, two recent studies have reported 
that oral BPs reduce mortality in osteoporotic patients and 
that the reduction in mortality could be mainly due to car-
diovascular and cerebrovascular deaths.91,92 On the contrary, 
a recent meta-analysis by Kim et al93 indicated that commonly 
prescribed BPs do not provide any clinically important 
benefits or harm with regard to cardiovascular events. The 
analysis of the studies included in this systematic review 
seems to suggest a positive effect of BPs on the progression 
of both atherosclerotic plaque and vascular calcifications. 
First of all, it is important to emphasize that this review has 
some limitations primarily resulting from the small sample 
size of most studies. Thus, insufficient data were available 
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to allow separate analysis of the effects of BPs in different 
patient subgroups. Moreover, most of these studies were of 
suboptimal quality in terms of providing adequate descrip-
tion of allocation concealment and the lack of the use of 
double blinding, thus leading to possible overestimation of 
BP benefit.
Several studies have shown that etidronate limited the 
progression of aortic and coronary calcification in hemo-
dialysis patients.81–83 Instead, the N-BPs given orally (alen-
dronate, risedronate and ibandronate) did not significantly 
reduce vascular calcifications either in patients with CKD85 
and kidney trasplant86 or in patients with osteoporosis88 and 
hypercholesterolemia.79 However, at present, the clinical 
use of etidronate should be considered with caution because 
this agent can cause impaired bone mineralization, which 
may lead to osteomalacia and to an increased risk of stress 
fractures. Moreover, particular attention is required when 
using BPs in CKD and hemodialysis patients because in these 
patients, BPs may excessively reduce bone turnover, ulti-
mately aggravating adynamic bone disease. Several studies 
have reported that BPs, especially N-BPs, present favorable 
effects both on vessel wall thickness and on the parameters of 
arterial elasticity and stiffness.72–76,79 A possible mechanism 
of action of N-BPs may be a slowing down of the formation 
of atherosclerotic plaques due to a reduction in serum lipids, 
which are considered responsible for the triggering of athero-
sclerosis progression. In fact, the majority of studies found 
a reduction in total and LDL-C along with a mild increase 
in HDL-C,69–72,74 whereas other studies did not report any 
changes.77,80 These controversial data may suggest that the 
effect of BPs on lipids depends on the administration route, 
with a more favorable effect found when given i.v. However, 
literature data suggest that the changes in lipids alone are not 
sufficient to explain the positive effect on atherosclerosis. 
Moreover, BPs, especially N-BPs, could have an indirect 
effect on atherosclerotic manifestations due to the interaction 
of BPs with the bone tissue, with the consequent release of 
bone turnover markers, bone-related hormones and cytokines 
(such as osteocalcin, fibroblast growth factor 23, osteopro-
tegerin and so on) into the bloodstream. As confirmation, a 
recent study reported that osteocalcin and fibroblast growth 
factor 23 were independent predictors of carotid IMT in 
postmenopausal women treated with zoledronate.72
To sum up, the BPs seem to have the potential of influ-
encing atherosclerosis and calcium homeostasis at the level 
of vascular walls with several possible mechanisms which 
may differ according to the type, potency, dosage and admin-
istration route of BPs. However, until the present time, it is 
not yet clear which of these above-mentioned mechanisms 
may be the most important in humans and additional studies 
are needed to specifically address the mechanism by which 
BPs use could influence cardiovascular morbidity and 
mortality.
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Tankó LB; PERF study group. Links between cardiovascular disease 
and osteoporosis in postmenopausal women: serum lipids or athero-
sclerosis per se? Osteoporos Int. 2007;18(4):505–512.
 14. Vogt MT, San Valentin R, Forrest KY, Nevitt MC, Cauley JA. Bone 
mineral density and aortic calcification: the study of osteoporotic frac-
tures. J Am Geriatr Soc. 1997;45(2):140–145.
 15. Hofbauer LC, Brueck CC, Shanahan CM, Schoppet M, Dobnig H. Vas-
cular calcification and osteoporosis from clinical observation towards 
molecular understanding. Osteoporos Int. 2007;18(3):251–259.
 16. Parhami F, Morrow AD, Balucan J, et al. Lipid oxidation products have 
opposite effects on calcifying vascular cell and bone cell differentia-
tion. A possible explanation for the paradox of arterial calcification 
in osteoporotic patients. Arterioscler Thromb Vasc Biol. 1997;17(4): 
680–687.
 17. Aikawa E, Nahrendorf M, Sosnovik D, et al. Multimodality molecular 
imaging identifies proteolytic and osteogenic activities in early aortic 
valve disease. Circulation. 2007;115(3):377–386.
 
Cl
in
ica
l I
nt
er
ve
nt
io
ns
 in
 A
gi
ng
 d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
19
3.
20
5.
6.
11
1 
on
 2
8-
M
ar
-2
01
8
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
Clinical Interventions in Aging 2017:12 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
1827
BPs, atherosclerosis and vascular calcification
 18. Aikawa E, Aikawa M, Libby P, et al. Arterial and aortic valve 
calcification abolished by elastolytic cathepsin S deficiency in chronic 
renal disease. Circulation. 2009;119(13):1785–1794.
 19. Bostrom K, Watson KE, Stanford WP, Demer LL. Atherosclerotic cal-
cification: relation to developmental osteogenesis. Am J Cardiol. 1995; 
75(6):88B–91B.
 20. Duer MJ, Friscic T, Proudfoot D, et al. Mineral surface in calcified 
plaque is like that of bone: further evidence for regulated mineraliza-
tion. Arterioscler Thromb Vasc Biol. 2008;28(11):2030–2034.
 21. Demer LL, Tintut Y. Mineral exploration: search for the mechanism 
of vascular calcification and beyond: the 2003 Jeffrey M. Hoeg Award 
lecture. Arterioscler Thromb Vasc Biol. 2003;23(10):1739–1743.
 22. Lusis AJ. Atherosclerosis. Nature. 2000;407(6801):233–241.
 23. Bostrom K, Demer LL. Regulatory mechanisms in vascular calcifica-
tion. Crit Rev Eukaryot Gene Expr. 2000;10(2):151–158.
 24. Sage AP, Tintut Y, Demer LL. Regulatory mechanisms in atheroscle-
rotic calcification. Nat Rev Cardiol. 2010;7(9):528–536.
 25. Bostrom K, Watson KE, Horn S, Wortham C, Herman IM, Demer LL. 
Bone morphogenetic protein expression in human atherosclerotic 
lesions. J Clin Invest. 1993;91(4):1800–1809.
 26. Steitz SA, Speer MY, Curinga G, et al. Smooth muscle cell phenotypic 
transition associated with calcification: up regulation of Cbfa1 and down 
regulation of smooth muscle lineage markers. Circ Res. 2001;89(12): 
1147–1154.
 27. Ikeda T, Shirasawa T, Esaki Y, Yoshiki S, Hirokawa K. Osteopontin 
mRNA is expressed by smooth muscle-derived foam cells in human ath-
erosclerotic lesions of the aorta. J Clin Invest. 1993;92(6):2814–2820.
 28. Murshed M, Schinke T, McKee MD, Karsenty G. Extracellular matrix 
mineralization is regulated locally; different roles of two gla-containing 
proteins. J Cell Biol. 2004;165(5):625–630.
 29. Schafer C, Heiss A, Schwarz A, et al. The serum protein alpha 2-Her-
emans-Schmid glycoprotein/fetuin-A is a systemically acting inhibitor 
of ectopic calcification. J Clin Invest. 2003;112(3):357–366.
 30. Ketteler M, Bongartz P, Westenfeld R, et al. Association of low fetuin-A 
(AHSG) concentrations in serum with cardiovascular mortality in 
patients on dialysis: a cross-sectional study. Lancet. 2003;361(9360): 
827–833.
 31. Lacey DL, Timms E, Tan HL, et al. Osteoprotegerin ligand is a 
cytokine that regulates osteoclast differentiation and activation. Cell. 
1998;93(2):165–176.
 32. Simonet WS, Lacey DL, Dunstan CR, et al. Osteoprotegerin: a novel 
secreted protein involved in the regulation of bone density. Cell. 1997; 
89(2):309–319.
 33. Bucay N, Sarosi I, Dunstan CR, et al. Osteoprotegerin-deficient mice 
develop early onset osteoporosis and arterial calcification. Genes Dev. 
1998;12(9):1260–1268.
 34. Morony S, Tintut Y, Zhang Z, et al. Osteoprotegerin inhibits vascu-
lar calcification without affecting atherosclerosis in ldlr (-/-) mice. 
Circulation. 2008;117(3):411–420.
 35. Bennett BJ, Scatena M, Kirk EA, et al. Osteoprotegerin inactivation 
accelerates advanced atherosclerotic lesion progression and calcifica-
tion in older ApoE-/- mice. Arterioscler Thromb Vasc Biol. 2006;26(9): 
2117–2124.
 36. Jono S, Ikari Y, Shioi A, et al. Serum osteoprotegerin levels are 
associated with the presence and severity of coronary artery disease. 
Circulation. 2002;106(10):1192–1194.
 37. Kiechl S, Schett G, Wenning G, et al. Osteoprotegerin is a risk factor 
for progressive atherosclerosis and cardiovascular disease. Circulation. 
2004;109(8):2175–2180.
 38. Ozkok A, Caliskan Y, Sakaci T, et al. Osteoprotegerin/RANKL axis and 
progression of coronary artery calcification in hemodialysis patients. 
Clin J Am Soc Nephrol. 2012;7(6):965–973.
 39. Schoppet M, Schaefer JR, Hofbauer LC. Low serum levels of soluble 
RANK ligand are associated with the presence of coronary artery disease 
in men. Circulation. 2003;107(11):e76.
 40. Kiechl S, Schett G, Schwaiger J, et al. Soluble receptor activator of 
nuclear factor-kappa B ligand and risk for cardiovascular disease. 
Circulation. 2007;116(4):385–391.
 41. Helas S, Goettsch C, Schoppet M, et al. Inhibition of receptor activator 
of NF-kappaB ligand by denosumab attenuates vascular calcium deposi-
tion in mice. Am J Pathol. 2009;175(2):473–478.
 42. Scatena M, Liaw L, Giachelli CM. Osteopontin: a multifunctional mol-
ecule regulating chronic inflammation and vascular disease. Arterioscler 
Thromb Vasc Biol. 2007;27(11):2302–2309.
 43. Wolak T. Osteopontin – a multi-modal marker and mediator in athero-
sclerotic vascular disease. Atherosclerosis. 2014;236(2):327–337.
 44. Shimada T, Kakitani M, Yamazaki Y, et al. Targeted ablation of FGF23 
demonstrates an essential physiological role of FGF23 in phosphate and 
vitamin D metabolism. J Clin Invest. 2004;113(4):561–568.
 45. Scialla JJ, Wolf M. Roles of phosphate and fibroblast growth factor 23 
in cardiovascular disease. Nat Rev Nephrol. 2014;10(5):268–278.
 46. Somjen D, Weisman Y, Kohen F, et al. 25-hydroxyvitamin D3–1alpha-
hydroxylase is expressed in human vascular smooth muscle cells and 
is upregulated by parathyroid hormone and estrogenic compounds. 
Circulation. 2005;111(13):1666–1671.
 47. Oh J, Weng S, Felton SK, et al. 1,25(OH)2 vitamin D inhibits foam cell 
formation and suppresses macrophage cholesterol uptake in patients 
with type 2 diabetes mellitus. Circulation. 2009;120(8):687–698.
 48. Giovannucci E, Liu Y, Hollis BW, Rimm EB. 25-hydroxyvitamin D 
and risk of myocardial infarction in men: a prospective study. Arch 
Intern Med. 2008;168(11):1174–1180.
 49. Bear M, Butcher M, Shaughnessy SG. Oxidized low-density lipoprotein 
acts synergistically with beta-glycerophosphate to induce osteoblast 
differentiation in primary cultures of vascular smooth muscle cells. 
J Cell Biochem. 2008;105(1):185–193.
 50. Lomashvili KA, Monier-Faugere MC, Wang X, Malluche HH, 
O’Neill WC. Effect of bisphosphonates on vascular calcification and 
bone metabolism in experimental renal failure. Kidney Int. 2009;75(6): 
617–625.
 51. Tamura K, Suzuki Y, Hashiba H, Tamura H, Aizawa S, Kogo H. Effect 
of etidronate on aortic calcification and bone metabolism in calcit-
riol treated rats with subtotal nephrectomy. J Pharmacol Sci. 2005; 
99(1):89–94.
 52. Ylitalo R, Oksala O, Ylä-Herttuala S, Ylitalo P. Effects of clodronate 
(dichloromethylene bisphosphonate) on the development of experimen-
tal atherosclerosis in rabbits. J Lab Clin Med. 1994;123(5):769–776.
 53. Lerman DA, Prasad S, Alotti N. Denosumab could be a potential inhibi-
tor of valvular interstitial cells calcification in vitro. Int J Cardiovasc 
Res. 2016;5(1):1.
 54. Samelson EJ, Miller PD, Christiansen C, et al. RANKL inhibition with 
denosumab does not influence 3-year progression of aortic calcifica-
tion or incidence of adverse cardiovascular events in postmenopausal 
women with osteoporosis and high cardiovascular risk. J Bone Miner 
Res. 2014;29(2):450–457.
 55. Mullard A. Merck &Co. drops osteoporosis drug odanacatib. Nat Rev 
Drug Discov. 2016;15(10):669.
 56. Luckman SP, Hughes DE, Coxon FP, Graham R, Russell G, Rogers MJ. 
Nitrogen-containing bisphosphonates inhibit the mevalonate pathway 
and prevent post-translational prenylation of GTP-binding proteins, 
including Ras. J Bone Miner Res. 1998;13(4):581–589.
 57. Fleisch HA, Russell RG, Bisaz S, Mühlbauer RC, Williams DA. The 
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